Cancer care: A microcosm of the problems facing all of health care

Annals of Internal Medicine

Volumn 150, Issue 8, 2009, Pages 573-576

  Wilson, Jennifer Fisher ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; HEALTH CARE COST; HUMAN; INTENSIVE CARE; KIDNEY CANCER; MEDICAL DECISION MAKING; PALLIATIVE THERAPY; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ARTICLE; COST OF ILLNESS; DECISION MAKING; ECONOMICS; ETHICS; HEALTH CARE DELIVERY; INTERPERSONAL COMMUNICATION; NEOPLASM; ONCOLOGY; STANDARD; UNNECESSARY PROCEDURE;

COST OF ILLNESS; DECISION MAKING; DELIVERY OF HEALTH CARE; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PROGNOSIS; TRUTH DISCLOSURE; UNNECESSARY PROCEDURES;

EID: 65349118113     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-150-8-200904210-00024     Document Type: Review

References (13)

1. Matsuyama R, Reddy S, Smith TJ. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol. 2006;24:3490-6. [PMID: 16849766]
2. Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS. Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med. 2003;138:639-43. [PMID: 12693886]
3. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22:315-21. [PMID: 14722041]
4. Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms. Two randomized trials. Ann Intern Med. 2009;150:16-27.
5. Avorn J, Shrank WH. Communicating drug benefits and risks effectively: there must be a better way. Ann Intern Med. 2009;150:563-4.
6. Pollak KI, Arnold RM, Jeffreys AS, Alexander SC, Olsen MK, Abernethy AP, et al. Oncologist communication about emotion during visits with patients with advanced cancer. J Clin Oncol. 2007; 25:5748-52. [PMID: 18089870]
7. Wright AA, Zhang B, Ray A, Mack JW, Trice E, Balboni T, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA. 2008;300:1665-73. [PMID: 18840840]
8. Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? [Letter]. J Clin Oncol. 2007;25:4506-7; author reply 4508. [PMID: 17906218]
9. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;l 1:90-5. [PMID: 16476830]
10. Medicare Payment Advisory Commission. Chapter 9: Medicare payments for outpatient drugs under Part B. In: Report to the Congress: Variation and Innovation in Medicare. June 2003. Accessed at www.medpac.gov/publications/ congressionaL reports/June03-Ch9.pdf on 17 March 2009.
11. Schrag D, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007;25:233-7. [PMID: 17210946]
12. Meropol NJ, Sdiulman KA. Cost of cancer care: issues and implications. J Clin Oncol. 2007; 25:180-6. [PMID: 17210937]
13. Oglesby P. The Caring Physician: The Life of Dr. Francis W. Peabody. Cambridge: Harvard Univ Pr; 1991.